Medmira AI Stock Analysis
Want to see TSE:MIR full AI Analyst Report?
Medmira (MIR) AI Stock Analysis
Medmira
(TSXV:MIR)
The overall score reflects very weak financial health and an unattractive valuation anchored by ongoing losses and negative equity, partially offset by a constructive technical setup with the price trading above key moving averages and showing moderate positive momentum.
Medmira (MIR) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 38.60M
- Dividend Yield
- ―
- Average Volume (3M)
- 82.43K
- Price to Earnings (P/E)
- -12.5
- Beta (1Y)
- 0.78
- Revenue Growth
- 45.72%
- EPS Growth
- 35.82%
- Country
- Canada
- Employees
- 52
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Medmira Business Overview & Revenue Model
Company Description
MedMira Inc. is a biotechnology company focused on the research, development, manufacturing, and global commercialization of rapid diagnostic solutions and related technology platforms. Its operations span North America, Europe, the Asia Pacific regi...
How the Company Makes Money
MedMira makes money primarily by selling diagnostic test kits and related consumables built on its RVF rapid testing platform. Revenue is generated when customers (e.g., clinics, hospitals, laboratories, government/public health agencies, and distrib...
Medmira Financial Statement Overview
Summary
Strong revenue growth is offset by persistent losses, negative equity, and continued cash burn, resulting in a weak but slightly improving overall financial profile.
Income Statement
24NegativeBalance Sheet
18Very NegativeCash Flow
21Negative| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 370.57K | 240.51K | 412.57K | 432.53K | 952.13K | 2.14M |
| Gross Profit | -1.66M | -990.25K | 226.49K | -434.91K | 304.03K | 1.72M |
| EBITDA | -1.75M | -3.13M | -2.13M | -1.58M | -1.07M | 185.30K |
| Net Income | -2.99M | -4.52M | -3.33M | -2.68M | -1.83M | -675.80K |
Balance Sheet | ||||||
| Total Assets | 3.40M | 3.68M | 6.07M | 3.65M | 3.83M | 3.89M |
| Cash, Cash Equivalents and Short-Term Investments | 0 | 14.91K | 2.10M | 13.18K | 33.46K | -2.30M |
| Total Debt | 17.42M | 10.71M | 9.56M | 9.27M | 8.30M | 11.54M |
| Total Liabilities | 27.92M | 26.24M | 24.11M | 18.68M | 16.19M | 19.61M |
| Stockholders Equity | -24.52M | -22.56M | -18.04M | -15.03M | -12.36M | -15.72M |
Cash Flow | ||||||
| Free Cash Flow | -1.19M | -3.15M | -3.68M | -1.27M | -1.95M | -541.19K |
| Operating Cash Flow | -1.19M | -3.15M | -2.94M | -1.27M | -1.88M | -504.64K |
| Investing Cash Flow | 0 | -7,468 | -742.53K | -1,267 | -69.72K | -36.55K |
| Financing Cash Flow | 1.17M | 1.07M | 5.77M | 1.25M | 1.99M | 139.32K |
Medmira Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MIR, the sentiment is Neutral. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.06, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 54.90 is Neutral, neither overbought nor oversold. The STOCH value of 133.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:MIR.
Medmira Peers Comparison
Overall Rating
TSE:COV79Outperform- TSE:MIR55Neutral
TSE:MBX52Neutral
TSE:NRX51Neutral
TSE:DTC44Neutral
TSE:SVA41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:COV | 79Outperform | CAD 121.24M | 27.08 | 15.04% | ― | 4.11% | 88.39% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TSE:MIR | 55Neutral | CAD 38.60M | -12.50 | 12.68% | ― | 45.72% | 35.82% |
| TSE:MBX | 52Neutral | CAD 41.78M | -8.36 | -18.83% | ― | -27.13% | -1752.63% |
| TSE:NRX | 51Neutral | CAD 37.71M | -4.52 | -337.24% | ― | ― | 19.02% |
| TSE:DTC | 44Neutral | CAD 25.50M | -2.81 | -424.91% | ― | ― | -54.70% |
| TSE:SVA | 41Neutral | CAD 41.54M | -3.74 | 57.10% | ― | ― | 48.06% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:MIR | Medmira Inc | 0.06 | -0.02 | -21.43% | |
| TSE:COV | Covalon Technologies | 4.26 | 2.27 | 114.07% | |
| TSE:MBX | Microbix Biosystms | 0.29 | 0.05 | 20.41% | |
| TSE:SVA | Sernova Corp | 0.11 | -0.03 | -18.52% | |
| TSE:NRX | Nurexone Biologic Inc. | 0.49 | -0.22 | -30.99% | |
| TSE:DTC | Defence Therapeutics Inc | 0.34 | -0.47 | -58.13% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 22, 2026